Summary
The United States District Court for the District of Delaware granted defendants’ motion to dismiss a shareholder derivative action brought on behalf of Bioventus Inc. The court held that the action was filed prematurely because approximately four weeks was insufficient time for the board to investigate the plaintiff’s demand, which involved numerous individuals, several years of alleged misconduct, multiple legal theories, and requested corporate governance reforms. The complaint was dismissed without prejudice.
Topics
Practice areas
Questions Presented
- Whether the derivative action was prematurely filed because the plaintiff filed suit only approximately four weeks after making a broad and complex demand on the board.
- Whether the amended complaint satisfied Federal Rule of Civil Procedure 23.1's demand and particularity requirements.
- Whether the action should be dismissed without prejudice pending the board's consideration of the demand and related derivative litigation.
Holdings
- A derivative complaint filed approximately four weeks after a demand was premature where the demand involved fifteen individuals, nearly four years of alleged misconduct, multiple potential legal claims, extensive financial and public-record review, and requested corporate-governance reforms.
- A derivative action filed before the board has had a reasonable opportunity to investigate a demand must be dismissed without prejudice.
Key quotations
“The question in premature filing cases is not how much time is needed to respond to the demand, but whether the time between demand and filing of suit was sufficient to permit the Board of Directors to discharge its duty to consider the demand.”
“The premature filing of a suit after a demand has been made frustrates the underlying policy of Rule 23.1, which is “that an individual shareholder ordinarily should not usurp the responsibility of corporate management to determine whether and how to pursue a corporate claim.””
Factual background
Bioventus, a medical device and pharmaceutical company, allegedly lacked effective controls for accounting for rebates associated with its products and consequently overstated revenue and EBITDA in public filings and statements. The company disclosed a correction to its rebate accruals in November 2022, prompting a securities class action that later settled. Plaintiff demanded that the board investigate and bring claims against fifteen current or former directors, officers, and agents based on alleged accounting failures, fiduciary breaches, corporate waste, unjust enrichment, and related matters. Plaintiff filed this derivative action approximately four weeks after making the demand, before the board had completed its investigation.
Procedural history
Plaintiff made a demand on Bioventus's board on February 6, 2025, requesting investigation and litigation concerning alleged accounting and internal-control failures and related misconduct. He filed the original derivative complaint approximately four weeks later in the Middle District of North Carolina. The action was transferred to the District of Delaware, and Plaintiff filed an amended complaint on September 3, 2025. The court concluded that the four-week period between demand and filing was insufficient for the board to investigate the extensive allegations and dismissed the action without prejudice.